Lisuride in de novo Parkinsonian patients: a four-year follow-up
Corresponding Author
P. Giovannini
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Address Paolo Giovannini M D Neurological Institute “C. Besta” Department of Neurology Center for Extrapyramidal Disorders Via Celoria, 11 20133 Milan ItalySearch for more papers by this authorG. Scigliano
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorI. Piccolo
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorP. Soliveri
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorI. Suchy
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Shering AG, Berlin (WG)
Search for more papers by this authorT. Caraceni
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorCorresponding Author
P. Giovannini
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Address Paolo Giovannini M D Neurological Institute “C. Besta” Department of Neurology Center for Extrapyramidal Disorders Via Celoria, 11 20133 Milan ItalySearch for more papers by this authorG. Scigliano
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorI. Piccolo
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorP. Soliveri
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorI. Suchy
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Shering AG, Berlin (WG)
Search for more papers by this authorT. Caraceni
Department of Neurology Center for Extrapyramidal Disorders, Institute of Neurology, “C. Besta”, Milan, Italy
Search for more papers by this authorAbstract
ABSTRACT— Lisuride at a mean daily dose of 3.2 mg was given to 15 untreated idiopathic Parkinson's disease patients. There were 10 dropouts, due mainly to inefficacy in the first months of therapy. The parkinsonian pattern in the patients who remained in the study for the full 4 years showed distinct improvement, which was maintained for less than 2 years. The patients did not develop “on-off” phenomena or abnormal involuntary movements during follow-up.
References
- 1 Calne D. B., Teychenne P. F., Claveria L. E., Eastman R, Greenacre J. K., Petrie A. Bromocriptine in parkinsonism. Br Med J 1974: 4: 442–443.
- 2 LeWitt P. A. Clinical and pharmacological aspects of the antiparkinsonian ergolene lisuride. In: S Fahn, C. D. Marsden, P Jenner, P Teychenne, eds. Recent developments in Parkinson's disease. New York: Raven, 1986: 347–354.
- 3 LeWitt P. A., Gopinathan G, Ward C. D., et al. Lisuride versus oromocriptine treatment in Parkinson disease: a double-blind study. Neurology (NY), 1982: 32: 69–72.
- 4 Loos D, Halbhubner K, Kehr W, Herken H. Action of dopamine agonists on Parkinson-like muscle rigidity induced by 6-aminonicotinamide. Neuroscience 1979: 4: 667–676.
- 5 Horowski R. Differences in the dopaminergic effects of the ergot derivatives, bromocriptine, lisuride, and d-LSD as compared with apomorphine. Eur J Pharmacol 1978: 51: 157–166.
- 6 Horowski R. Hypotermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics. Arch Pharmacol 1979: 306: 147–151.
- 7 Carruba M. O., Ricciardi S, Muller E. E., Mantegazza P. Anorectic effect of lisuride and other ergot derivatives in the rat. Eur J Pharmacol 1980: 64: 133–141.
- 8 Horowski R, Wachtel H. Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 1976: 36: 373–383.
- 9 Hara K, Ikoma Y, Oshino N. Effects of an ergot derivative, lisuride, on the central dopaminergic system: studies of behavioral pharmacology. Nippon Yakurigaku Zasshi 1982: 80: 1–13.
- 10 Kehr W. Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. Eur J Pharmacol 1977: 41: 261–273.
- 11 Da Prada M, Bonetti E. P., Keller H. H. Induction of mounting behaviour in female and male rats by lisuride. Neurosci Lett 1977: 6: 349–353.
- 12 Silbergeld E. K., Hruska R. E. Effects of ergot drugs on serotonergic function: behavior and neurochemistry. Eur J Pharmacol 1979: 58: 1–10.
- 13 Caraceni T, Giovannini P, Parati E, Scigliano G, Grassi M. P., Carella F. Bromocriptine and lisuride in Parkinson's disease. In: R. G. Hassler, J. C. Christ, eds. Advances in neurology, vol. 40. New York: Raven, 1984: 531–535.
- 14 Giovannini P, Scigliano G, Grassi M. P., Carella F, Parati E, Caraceni T. Bromocriptine-lisuride cross tolerance. Ital J Neurol Sci 1983: 1: 129–130.
- 15 Schachter M, Sheehy M. P., Parkers J. D., Marsden C. D. Lisuride in the treatment of parkinsonism. Acta Neurol Scand 1980: 62: 382–385.
- 16 Gopinathan G, Teravainen H, Dambrosia J. M., et al. Lisuride in parkinsonism. Neurology (NY) 1981: 31: 371–376.
- 17 Lees A. J., Stern G. M. Pergolide and lisuride for levodopa-induced oscillations. Lancet, 1981: 2: 577.
- 18 LeWitt P. A., Calne D. B. Experience with dopamine agonists in Parkinson's disease and related disorders. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 473–480.
- 19 Rinne U. K. New ergot derivatives in the treatment of Parkinson's disease. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 431–442.
- 20 Lieberman A. N., Goldstein M. M., Gopinathan G, et al. Lisuride in Farkinson's disease and related disorders. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 419–429.
- 21 Ulm G. Experience with lisuride in the treatment of Parkinson's disease. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 463–472.
- 22 Birkmayer W, Riederer P. Effects of lisuride on motor function, psychomotor activity, and psychic behavior in Parkinson's disease. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 453–461.
- 23 Riederer P, Reynolds G. P., Danielsczyk W, Jellinger K, Seeman D. Desensitization of striatal spiperone binding sites by dopaminergic agonists in Parkinson's disease. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 375–381.
- 24 Agnoli A, Ruggieri A, Baldassarre M, Stocchi F, Denaro A, Falaschi P. Dopaminergic ergots in parkinsonism. In: D. B. Calne, et al eds. Lisuride and other dopamine agonists: basic mechanisms and endocrine and neurological effects. New York: Raven, 1983: 407–417.
- 25 Duvoisin R. C., Mendoza M, Yahr M. D. A comparative study of bromocriptine and levodopa in Parkinson's disease. In: M Goldstein, et al eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven, 1980: 271–275.
- 26 Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease. In: Fahn et al, eds. Recent developments in Parkinson's disease. New York: Raven, 1986: 267–271.
- 27 Lees A. J., Stern G. M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. Res Clin Forums 1981: 3: 29–32.
- 28 Calne D. B., Stoessl J. Approaches to the use of bromocriptine in Parkinson's disease. In: S Fahn, et al eds. Recent developments in Parkinson's disease. New York: Raven, 1986: 255–258.
- 29 Rinne U. K. Dopamine agonists in the treatment of Parkinson's disease. Adv Neurol 1983: 37: 141–150.
- 30 Rascol A, Montastruc J. L., Rascol O. Should dopamine agonists be given early or late in the treatment of Parkinson's disease. Can J Neurol Sci 1984: 11: 229–232.
- 31 Calne D. B. Dopamine receptors in movement disorders. In: C. D. Marsden, S Fahn, eds. Movement disorders. London: Butterworth, 1982: 348–355.
- 32 Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M. Dopamine receptor changes in response to prolonged treatment with L-dopa. J Neurol Transm (Suppl.) 1986: 22: 33–45.
- 33 Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: C. D. Marsden, S Fahn, eds. Movement disorders. London: Butterworth, 1982: 123–145.
- 34 Lieberman A. N., Gopinathan G, Hassouri H, Neophytides A, Goldstein M. Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine. Can J Neurol Sci 1984: 11: 233–237.
